Introduction
The Na,K-ATPase is the enzymatic equivalent of the Na,Kpump (1) (2) (3) , and as such, it has many critical functions, including maintenance of cellular Na and K concentrations and establishment oftransmembrane electrochemical gradients. The possibility that there might be important abnormalities at the level of the membrane Na,K-ATPase in patients with chronic renal failure (CRF)' was first suggested nearly 20 yr ago, with the pioneering studies of Welt et al. (4) . Using the Na,K-ATPase of erythrocyte membranes as a model system, these workers found abnormalities of this enzyme-transport system in a subgroup (-25%) of patients with CRF. The abnormalities present in these patients included: (a) increased cell Na concentration; (b) reduced membrane Na,K-ATPase enzymatic activity; and (c) reduced rate constant for Na efflux via the Na,K pump. Further, these patients had a factor in plasma that, upon exposure to normal cells, could reduce subsequently measured Na,K-ATPase activity and pump-mediated Na efflux (5) . Finally, in very limited studies, the defect was seen to be diminished after chronic dialysis (6) .
Over the subsequent years, abnormalities involving the erythrocyte Na,K-ATPase have been described in several other groups of CRF patients (7-1 1) and alterations in Na,K-ATPase enzyme or transport activity have been seen in leukocytes (12, 13) , muscle cells (14) , intestine (15) , and brain (16) in CRF as well. However, despite the potential importance of a defect at the level of Na,K-ATPase in the genesis of uremia, a clear understanding of the nature of the abnormality and its correction by hemodialysis has not emerged. At least two reasons for this are apparent. First, and most obvious, is heterogeneity ofpatient groups, since patients with varying degrees of renal failure have been studied, both before and after institution of dialysis. A second, and more subtle problem has been heterogeneity of the methods used to study the Na,K-ATPase. This problem arises from the fact that there are several different ways in which the Na,K-ATPase can be probed, including (a) the specific binding of the inhibitory ligand [3H]ouabain, which can be used to determine the number of Na,K pump units; (b) the activity of membrane Na,K-ATPase as a function ofvarying concentrations of substrates and ions, which measures the enzymatic function of the protein; and (c) the rates of specific Na,K-ATPase-mediated transport of Na and/or K across cell membranes, which assess the transport function of the enzyme-pump.
In this study, we have combined measurements of the num- 
Results
Binding of [3H]ouabain to human erythrocytes is a high affinity, saturable process (18) , and the receptor for [3H]ouabain in this, as in other cells, is the Na,K-ATPase enzyme. Under the conditions used in these experiments, the number of [3H]ouabain binding sites is determined at saturating concentrations of the ligand, at which Na,K pump-mediated ion transport is completely inhibited (19) . This is true both in cells from control (19) and CRF patients ( Fig. 1 ). Fig. 2 shows the values for saturable ouabain binding to erythrocytes of control subjects, and CRF patients before and after 4 h of hemodialysis. In each group, saturable ouabain binding is seen to vary over a three-to fourfold range, as seen in studies of erythrocyte ouabain binding in other patient groups In contrast to these findings for Na,K pump number (i.e., saturable ouabain binding), erythrocytes from the same CRF patients had a reduced rate of pump-mediated 86Rb uptake when compared with control ( Fig. 3, left) . Thus, the mean rate of pump-mediated 86Rb uptake was 139.23±22.37 nM/109 cells per h in controls and 104.99±24.13 nM/ 109 cells per h in CRF patients before dialysis, which represents a mean reduction of 30% (Fig. 3, left) . Pump-independent 86Rb uptake was not significantly different in patients and controls (52.84±14.39 vs. 60.56±17.86 nM/109 cells per h, P = NS) (Fig. 3, right) .
Unlike ouabain binding, which was unaffected by dialysis ( Fig. 2) , pump-mediated 86Rb uptake was acutely increased after hemodialysis in these patients (Fig. 4, left) . Pump-mediated 86Rb uptake was 104.99±24.13 nM/109 cells per h predialysis, and 124.90±27.72 nM/109 cells/h after 4 h ofdialysis. In addition to this significant mean 20% difference in pump activity (P < 0.001), it is seen that the rate of pump-mediated 86Rb uptake rose in 17 of 18 studies. The degree of rise ranged from 3% to as much as 50% and the mean delta pump activity was +21% (P < 0.001). Hemodialysis had a variable effect on the pumpindependent 86Rb uptake (Fig. 4, right) , but there was no significant change in the mean level of this parameter as a result of dialysis. 583 Erythrocyte Na,K Pump in Uremia . Acute effect of hemodialysis on pump-mediated and pumpindependent 86Rb uptake into erythrocytes. The effect of 4 h of hemodialysis upon pump-mediated (left) and pump-independent (right) 86Rb uptake into erythrocytes of CRF patients. The mean rise in pump-mediated 86Rb uptake after dialysis was 20% (P < 0.001).
To better illustrate the nature of the abnormality in Na,K pump function, we have graphed individual values for [3HJouabain binding as a function of pump-mediated 86Rb uptake in control and CRF patients before dialysis (Fig. 5) , and in CRF patients pre-and post-dialysis (Fig. 6) . In each situation, there is a positive correlation between the number of [3H]ouabain binding sites and pump-mediated 86Rb uptake: i.e., r = 0.726, P < 0.002 in control, r = 0.722, P < 0.002 predialysis, and r = 0.541, P < 0.05 postdialysis. This confirms previous findings from our (17) and other laboratories (20, 21) . However, it is evident that the correlation line is shifted downward in predialysis renal failure patients when compared with controls (Fig. 5) . Thus, at any given level of ouabain binding, which reflects the number of Na,K pump units, there is less pump-mediated 86Rb uptake in CRF patients before dialysis. This suggests that Na,K pump units are pumping 86Rb less efficiently in CRF patients before dialysis. It is also evident that dialysis was associated with an acutely increased rate of pump-mediated 86Rb uptake at an unchanged level of specific ouabain binding, so that the correlation line between these two parameters returned towards that of controls (Fig. 6) . Taken together, these data suggest that A. 4 hemodialysis may remove a factor that inhibits Na,K pumpmediated 86Rb influx.
The mean values for cellular Na concentration were 5.38±1.20 meq/liter of cells in controls, 5.77±1.78 meq/liter of cells in predialysis CRF patients, and 6.15±1.40 meq/liter ofcells in postdialysis patients. These values are not significantly different, although two patients with CRF had values for intracellular Na that were higher than any controls (10.2 and 10.4 meq/liter of cells). Since the intracellular Na concentration is an important regulator of the rate of Na,K pump tumover, we attempted to determine whether the degree to which pump activity increased after dialysis was a function of the initial intracellular sodium concentration, and no significant correlation between these two parameters was found (r = 0.157). Furthermore, there was no significant correlation between the extent of rise in pump-mediated 86Rb uptake after dialysis and any change (either a rise or fall) in the cell Na concentration (r = 0.132) (Fig. 7) . This is true whether Na is expressed per liter of cells or per I09 cells (data not shown). These data suggest that the increase in pump-mediated 86Rb uptake seen after dialysis was not caused by a rise in the intracellular concentration of sodium. Table I summarizes the mean values of several parameters that were measured pre-and post-hemodialysis. The extent to which pump activity increased did not correlate with serum levels of Na, K, pH, BUN or creatinine before or after dialysis. However, there was a significant correlation between the extent of rise in pump-mediated 86Rb uptake and the weight loss that occurred during the course of dialysis (r = 0.517, P = 0.02) (Fig. 8) . Thus, the greatest rise in 86Rb transport was seen in those individuals who lost the most weight during hemodialysis.
We also performed a digoxin radioimmunoassay with these sera to assess the possibility that some patients might have been a CELL [Na] (mmol/liter cells) Figure 7 . Correlation between the change in erythrocyte Na concentration during dialysis and the change in pump-mediated 86Rb uptake during dialysis in 15 subjects. exposed to digitalis, or that an endogenous digitalis-like molecule with cross-reactivity in this assay (22) might be present. There was no significant displacement in the digitalis radioimmunoassay by any sera from controls, predialysis CRF patients, or postdialysis CRF patients (data not shown).
Finally, we attempted to determine whether the apparent inhibition of pump activity that predialysis cells manifested was mediated by a factor present in predialysis serum. Fig. 9 shows the specific ouabain binding and pump-mediated 86Rb uptake of normal erythrocytes after exposure to sera removed from patients either pre-or postdialysis. The level of [3Hlouabain binding was the same after cells were exposed to pre-or postdialysis serum. In contrast, pump-mediated 86Rb uptake was lower in cells exposed to predialysis serum than in cells exposed to postdialysis serum. The mean difference was 22.6% (n = 9, P < 0.01). In two experiments, normal cells exposed to postdialysis sera had a level of pump activity equal to the level seen after exposure of the cells to normal serum (data not shown). This suggests the existence of a serum factor in predialysis CRF patients that is capable of inhibiting Na,K pump activity.
Discussion
Since the pioneering studies of Welt et al. (4) , there has been considerable interest in the possibility that chronic renal failure may lead to physiologically important abnormalities in the function of the Na,K-ATPase enzyme-pump. Although studies 585 Erythrocyte Na,K Pump in Uremia with erythrocytes (4-1 1), leukocytes (12, 13) , and muscle (14) have produced a consensus that some abnormality at the level of Na,K-ATPase exists in many patients, the nature of the abnormality and its frequency in defined populations have remained unclear. Variations in patient populations and in methods used to study the Na,K-ATPase may be responsible for this fact.
In the current study, we have used several means to assess the status oferythrocyte Na,K-ATPase in a group ofchronically hemodialyzed patients with chronic renal failure, both before and immediately after hemodialysis. The data indicate that the erythrocytes of these chronically hemodialyzed patients have a specific reduction in the rate of86Rb uptake mediated by a given (normal) number of Na,K-pump units. Furthermore, this inhibition in pump turnover is acutely reversed by hemodialysis, and appears, through the results of in vitro incubation studies, to be mediated by a serum factor. Any study of the Na,K-ATPase in disease must take note ofthe varying methodologies used to probe this complex enzymepump. Determinations of the number of enzyme units must be distinguished from probes ofthe ion (K or Na) transport function of the enzyme, and these must in turn be distinguished from assays of the ATPase function of the enzyme. By studying two or more of these parameters in the same cells, greater insight into abnormalities can be gained.
We have used [3H]ouabain as a probe to assess the number of Na,K-ATPase units expressed in erythrocyte membranes (20) . This technique is based upon the knowledge that ouabain binds with high affinity and specificity to the Na,K-ATPase, with an apparent stoichiometry of 1:1. As expected, the level of saturable ouabain binding correlates very well with the maximal Na,KATPase activity in plasma membranes (21), and once bound to ouabain, the activity of the enzyme-pump is completely inhibited. Under the conditions used for [3H]ouabain binding in these experiments, the ligand saturates high affinity binding sites in cells of control and CRF patients and completely inhibits pump-mediated K transport activity (19) . Thus, our technique provides a valid index of Na,K-pump number in these cells.
Using this approach, erythrocytes from these CRF patients did not differ from controls with respect to the level ofsaturable ouabain binding. Because, under these assay conditions (37°C, 1 h), ouabain concentrations <40 nM have not reached equilibrium, we cannot perform Scatchard plots to determine the actual affinity of ouabain binding. However, the concentration of ouabain that half-saturates the binding sites at 1 h should reflect the binding affinity, and this parameter was also the same in CRF patients as in control, i.e., 7 nM (data not shown). Whereas ouabain binding capacity did not differ between cells previously exposed to pre-or post-dialysis serum (left), pump-mediated 86Rb uptake was 22.6% lower in cells exposed to pre-vs. post-dialysis serum (right).
Although of interest, the finding that saturable ouabain binding was the same in CRF and controls should not be overemphasized. First, we did not carefully study the hematologic status of these patients and thus, the number of ouabain binding sites could be influenced by erythrocyte factors apart from any specific regulation ofNa,K pump density. Second, many ofthese patients received periodic transfusions over the previous months, and thus, precise quantitation of the patients' Na,K pump density by ouabain binding techniques could be subject to some transfusion artifacts. However, the finding of normal ouabain binding is unambiguously important when taken in context with several other observations, most importantly, measurements of pumpmediated 86Rb uptake.
Thus, despite their "normal" number of specific ouabain binding sites, these cells had a clearly reduced rate of pumpmediated 86Rb uptake. The specificity of this effect is suggested by the normal level of pump-independent transport. The nature of this defect in pump-mediated 86Rb transport is best seen when we plot pump-mediated 86Rb transport as a function of specific ouabain binding. It is clear that Rb transport is a function of pump density in both control and CRF patients, as we have previously shown (17) , but that CRF patients before dialysis have a different correlation line between these two parameters.
At any pump density, as assessed by ouabain binding, pumpmediated Rb uptake is reduced.
The effect of 4 h of hemodialysis upon these parameters adds further strength to our observations. In these experiments, in which each patient serves as his own control, we see that whereas specific ouabain binding was unaffected by dialysis, pump-mediated 86Rb uptake (but not pump-independent uptake) rose after dialysis in 17 of 18 studies. The nearly universal nature of this effect, and its large magnitude in many patients underscore the importance of this observation. Although a rapid effect of hemodialysis upon the activity of the erythrocyte Na,K pump has not previously been observed, there is a precedent for hemodialysis having an acute effect upon an erythrocyte ion transport system. Thus, erythrocyte sodiumlithium countertransport was shown to be acutely influenced by ultrafiltration and hemodialysis in a group of patients with end stage renal disease due to hypertension (23) . In this study, in contrast to our own, dialysis acutely decreased the rate of countertransport, an effect postulated to be secondary to removal by dialysis of a necessary cofactor for the sodium-lithium countertransport process. As in our study, exposure of normal cells to pre-or post-dialysis plasma produced coordinate changes in the rate of countertransport (23) .
We have taken several approaches to further elucidation of the basis for these effects. Our first approach was to test the hypothesis that the inhibition of pump activity was related to a serum factor. We exposed normal cells to normal serum or to pre-or post-dialysis sera of CRF patients, washed, and then assessed ouabain binding and 86Rb uptake as we did for patients' cells removed before and after dialysis in vivo. When compared with normal or postdialysis sera, predialysis serum consistently inhibited pump-mediated 86Rb uptake, without affecting the level of specific ouabain binding. This confirmed the presence of a serum factor and suggested, as did the data with the patients' own cells, that the inhibitor was not a ouabainlike molecule that bound tightly to the ouabain binding site on the Na,KATPase. In preliminary studies (Izumo, H., in preparation), there was an excellent correlation between the changes in 86Rb uptake after serum exposure in vitro and those seen in erythrocytes of the dialyzed patients from whom the serum was derived. Studies to elucidate the chemical nature of the pump inhibitor described herein are currently in progress.
What is the mechanism of Na,K-pump inhibition? An obvious question relates to a possible role for changes in the level of erythrocyte sodium, since, under normal circumstances the enzyme functions near the Michaelis constant for sodium and therefore, the cell concentration of sodium could influence pump activity. Although measurements of cell Na are less precise than those of 86Rb uptake, the available data do not suggest an important role for cell sodium in either the depressed pumping rate predialysis, or the increase in pumping rate postdialysis. Neither did the pumping rate correlate with pre-or post-dialysis values of serum Na, K, pH, BUN, or creatinine. Thus, the putative pump inhibitor of uremia would appear to be acting to inhibit pump function by a mechanism that is not currently defined.
Although a preliminary observation, we observed a significant correlation between the extent of rise in pump-mediated 86Rb 587 Erythrocyte Na,K Pump in Uremia uptake and the amount of weight loss during hemodialysis. A similar correlation has recently been reported in preliminary form by using ouabain-inhibitable Na efflux as the means of assessing pump activity (24) . Further studies to assess the independent effects of dialysis and ultrafiltration will be necessary to clarify the meaning of this relationship. If more extensive studies show that the extent of pump inhibition is related to the degree of volume overload, the inhibitor might be seen as a natriuretic factor, acting through inhibition of the Na,KATPase.
In conclusion, the novel aspects of this study are worthy of review. (a) We have shown, using each patient as his/her own control, that nearly all CRF patients on chronic hemodialysis have a defect in the activity ofthe Na,K pump. This prevalence exceeds the 25% figure reported by Welt et al. (4) . (b) We have defined the nature of this prevalent defect to be a reduced Rb pumping rate despite a normal number ofpump units, a finding not previously documented. (c) We have provided evidence that this defect is caused by a serum factor that is present in pre-, but not post-dialysis serum. (d) We have shown that the pump inhibition is acutely reversed by hemodialysis. In a limited number ofpatients previously reported (6), hemodialysis over a period of many weeks improved pump activity, but an immediate effect of dialysis has not been reported. (e) We suggest, through the correlation of pump disinhibition with weight loss during dialysis, that volume expansion might be a regulatory factor in the genesis of the Na,K pump inhibitor.
Future studies will be necessary to determine the identity of the inhibitory factor, the precise mechanism by which it inhibits the Na,K pump and the factors that regulate its synthesis and clearance. These studies could be important for our understanding of the pathogenesis of uremia, as well as our understanding of the regulation of the Na,K-ATPase.
